balance equationreview2023-12-31
Difference 198462000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
Revenue
$120.77M
Fiscal year ended 2025-12-31Operating income
$35.86M
Fiscal year ended 2025-12-31Free cash flow
-$50.94M
Fiscal year ended 2025-12-31Valuation, from the filing
| Public float | $38.73M | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30 |
|---|---|---|
| Float per share | $4.74 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
| Float / net income | 1.2× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / revenue | 0.3× | A lower bound on the multiple, because affiliate holdings are excluded. |
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.
How this compares in its industry
Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
| Measure | Reported | Percentile | |
|---|---|---|---|
| CapEx / revenue | 0.0% | 0th | |
| Operating margin | 29.7% | 91th | |
| Effective tax rate | 0.1% | 12th | |
| Net margin | 27.1% | 88th | |
| R&D / revenue | 31.0% | 16th | |
| Current ratio | 0.82x | 16th | |
| SBC / revenue | 8.1% | 18th | |
| FCF margin | -42.2% | 69th | |
| Revenue YoY growth | -6.3% | 40th |
Atara Biotherapeutics, Inc. (ATRA) reported revenue of $120.77M and net income of $32.69M for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Atara Biotherapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | $120.77M | $128.94M | $8.57M | $63.57M |
| Cost of revenue | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross profit | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating income | $35.86M | -$83.44M | -$276.01M | -$280.51M |
| Net income | $32.69M | -$85.40M | -$276.13M | -$228.30M |
| Research & development | $37.44M | $151.48M | $224.78M | $272.53M |
| Weighted-average diluted shares | shares 12.72M | shares 7.49M | shares 4.24M | shares 101.99M |
| Pretax income | $32.72M | -$85.42M | -$276.11M | -$228.29M |
| Income tax expense | $31.00K | -$12.00K | $15.00K | $12.00K |
| Diluted EPS | $2.57 | $-11.41 | $-65.19 | $-2.24 |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable | Unavailable |
| General & administrative | $26.25M | $39.89M | $50.91M | $71.55M |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash & equivalents | $8.48M | $25.03M | $25.84M | $92.94M |
| Total assets | $20.24M | $109.10M | $165.50M | $376.42M |
| Current assets | $12.21M | $64.89M | $101.87M | $295.08M |
| Total liabilities | $58.74M | $206.38M | $264.74M | $249.78M |
| Current liabilities | $14.92M | $134.57M | $142.23M | $78.92M |
| Total equity incl. NCI | -$38.50M | -$97.28M | $99.23M | $126.64M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $0 | $10.66M | $9.71M | $1.59M |
| Accounts receivable | $1.25M | $1.48M | $34.11M | $40.22M |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts payable | $127.00K | $4.37M | $3.68M | $6.87M |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Operating cash flow | -$50.94M | -$68.72M | -$192.98M | -$270.43M |
| Capital expenditures | $0 | $246.00K | $1.22M | $4.19M |
| Investing cash flow | $18.15M | $8.62M | $123.87M | $202.96M |
| Financing cash flow | $16.10M | $59.28M | $2.01M | $53.08M |
| Net change in cash | Unavailable | Unavailable | Unavailable | Unavailable |
| Stock-based compensation | $9.75M | $27.00M | $45.39M | $53.84M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | $2.12M | $5.05M | $4.83M | $5.65M |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free cash flow | -$50.94M | -$68.96M | -$194.20M | -$274.62M |
| Gross margin | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating margin | 29.7% | -64.7% | -3219.5% | -441.2% |
| FCF margin | -42.2% | -53.5% | -2265.3% | -432.0% |
| SBC / revenue | 8.1% | 20.9% | 529.4% | 84.7% |
| Current ratio | 0.82x | 0.48x | 0.72x | 3.74x |
| Revenue YoY growth | -6.3% | 1404.0% | -86.5% | Unavailable |
| Net margin | 27.1% | -66.2% | -3220.9% | -359.1% |
| R&D / revenue | 31.0% | 117.5% | 2622.0% | 428.7% |
| CapEx / revenue | 0.0% | 0.2% | 14.3% | 6.6% |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 0.1% | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ATRA in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-15View SEC filing
Reconciliation checks needing review
1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.